Artificial Intelligence in Healthcare — MCQs
Which of the following screening methods is primarily used under the National Tuberculosis Elimination Program (NTEP)?
Which of the following statements about the DOTS treatment for tuberculosis is correct?
Based on the provided image, which of the following is the correct diagnosis?
A doctor is not held guilty of negligence if
After IV drug administration, elimination of a drug depends on:
A hospital implements blockchain technology for maintaining electronic health records. Compared to traditional centralized database systems, what is the primary advantage that justifies this innovation from a healthcare quality perspective?
A biotech company proposes using induced pluripotent stem cells (iPSCs) derived from patient fibroblasts to generate personalized cardiomyocytes for myocardial infarction treatment. What is the most significant ethical and technical challenge that must be addressed before clinical application?
An AI algorithm trained on chest X-rays from a single tertiary care center shows 95% accuracy in detecting tuberculosis. When deployed in a rural primary health center, accuracy drops to 68%. Which factor most likely explains this discrepancy?
A pharmaceutical company develops a new checkpoint inhibitor targeting LAG-3 (Lymphocyte Activation Gene-3) for melanoma. Compared to PD-1 inhibitors, what advantage would combination therapy with both agents theoretically provide?
A 62-year-old diabetic patient is enrolled in a telemedicine program with remote monitoring. His continuous glucose monitor shows nocturnal hypoglycemia at 3 AM for three consecutive nights, but morning fasting glucose is elevated at 180 mg/dL. What is the most appropriate next step?
Artificial Intelligence in Healthcare Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following screening methods is primarily used under the National Tuberculosis Elimination Program (NTEP)?
- A. Active
- B. Passive (Correct Answer)
- C. Mass
- D. None of the options
Explanation: ***Passive*** - Under the NTEP, **passive screening** involves individuals presenting to health facilities with symptoms suggestive of TB. - This method relies on **patient self-reporting** and healthcare provider suspicion, rather than active outreach. - Passive case finding is the **primary screening strategy** used across the general population in the NTEP framework. *Active* - **Active screening** involves community-based interventions to proactively identify individuals with TB, often in high-risk populations. - While active case finding is crucial for specific vulnerable groups (contacts, HIV patients, etc.), it is **not the primary screening method** under the standard NTEP framework for initial detection across the entire population. *Mass* - **Mass screening** involves testing large numbers of people in the general population, regardless of symptoms, to detect disease. - This is generally **cost-prohibitive** and not routinely implemented as a primary screening strategy for TB by the NTEP due to resource limitations and low yield in the general population. *None of the options* - **Passive screening** is indeed a primary method used under the NTEP, making this option incorrect. - The NTEP heavily relies on individuals seeking care when they experience symptoms, which aligns with the definition of passive case finding.
Question 2: Which of the following statements about the DOTS treatment for tuberculosis is correct?
- A. Case finding 80%, cure rate 85%
- B. Case finding 80%, cure rate 80%
- C. Case finding 70%, cure rate 75%
- D. Case finding 70%, cure rate 85% (Correct Answer)
Explanation: ***Case finding 70%, cure rate 85%*** - The **DOTS strategy** set a global target of detecting at least **70% of new sputum smear-positive TB cases** and curing at least **85% of these cases**. - Achieving these targets was considered crucial for controlling the spread of **tuberculosis** at a population level. *Case finding 80%, cure rate 85%* - While a **cure rate of 85%** is a key target of the DOTS strategy, the **case finding target was not 80%**. - Setting a higher case finding target might be desirable, but the **established goal** for DOTS was slightly lower to be more achievable. *Case finding 80%, cure rate 80%* - Neither the **case finding target nor the cure rate target** for DOTS was 80%. - The **cure rate target** was specifically emphasized as being higher to ensure effective treatment outcomes and prevent drug resistance. *Case finding 70%, cure rate 75%* - While **case finding 70%** aligns with the DOTS target, the **cure rate target was higher than 75%**. - A lower cure rate would indicate less effective treatment management, potentially leading to **treatment failures** and the emergence of **multidrug-resistant TB**.
Question 3: Based on the provided image, which of the following is the correct diagnosis?
- A. Uterus didelphys
- B. Bicornuate Uterus
- C. Unicornuate Uterus (Correct Answer)
- D. Septate uterus
Explanation: ***Unicornuate Uterus*** - The image distinctly shows **only one fallopian tube and one rudimentary uterine horn** on the right side, indicating a unicornuate uterus. - This malformation results from the **incomplete development of one Müllerian duct**, leading to a single, banana-shaped uterine cavity. *Uterus didelphys* - This condition involves **two completely separate uteri**, each with its own cervix and vagina. - The image does not show evidence of two distinct uterine bodies or cervices. *Bicornuate Uterus* - A bicornuate uterus is characterized by **two uterine horns that fuse caudally**, creating a heart-shaped appearance with a shared cervix. - The image clearly lacks the characteristic heart shape and shows only one functional horn. *Septate uterus* - A septate uterus has a **fibrous or muscular septum** dividing the uterine cavity, while the external uterine contour remains normal. - The image does not show a septum or a normal external uterine contour with an internal division; instead, it presents with a single underdeveloped horn.
Question 4: A doctor is not held guilty of negligence if
- A. He has not obtained informed consent from patient
- B. He has exercised reasonable care and skill (Correct Answer)
- C. Others suffer disease from his patient
- D. He fails to give proper instructions
Explanation: ***He has exercised reasonable care and skill*** - A doctor is not held guilty of **negligence** if they have acted in accordance with a practice accepted as proper by a responsible body of medical men skilled in that particular art (**Bolam test**). - This implies employing the **degree of care, diligence, and skill** that a reasonably competent practitioner would use under similar circumstances. *He has not obtained informed consent from patient* - Failure to obtain **informed consent** can lead to liability for **battery** (unlawful touching) or negligence, especially if the patient can prove they would not have undergone the procedure had they been properly informed of the risks. - Ethical and legal standards mandate that patients provide **voluntary, informed consent** before medical interventions. *Others suffer disease from his patient* - A doctor's primary responsibility is to their patient; however, there are situations where a **duty to warn** third parties exists, especially in cases of foreseeable harm from a communicable disease or dangerous psychiatric patient. - Failure to warn when such a **duty is established** could lead to negligence claims if specific harm to identifiable third parties occurs. *He fails to give proper instructions* - Providing **clear and adequate post-operative or post-treatment instructions** is a fundamental part of a doctor's duty of care. - Failure to give proper instructions can result in **patient harm** and can be grounds for a negligence claim if it leads to complications or a poor outcome.
Question 5: After IV drug administration, elimination of a drug depends on:
- A. Lipid solubility
- B. Volume of distribution
- C. Clearance (Correct Answer)
- D. All of the options
Explanation: ***Clearance*** - **Clearance (CL)** is the primary and direct determinant of drug elimination after IV administration. - It represents the **volume of plasma cleared of drug per unit time** (e.g., mL/min or L/hr). - The **rate of elimination** is directly calculated as: Rate = CL × Plasma concentration - Clearance integrates the efficiency of all eliminating organs (liver, kidneys) and is the key parameter determining how fast a drug is removed from the body. - Formula: **CL = Rate of elimination / Plasma concentration** *Lipid solubility* - Lipid solubility affects drug **distribution** and **renal reabsorption** but does not directly determine the rate of elimination. - Highly lipid-soluble drugs may be reabsorbed in renal tubules, but the elimination rate is still governed by clearance. - Lipid solubility is more relevant to drug distribution and metabolism pathways than to the rate of elimination itself. *Volume of distribution* - Volume of distribution (Vd) describes how extensively a drug distributes into tissues versus plasma. - While Vd affects the **half-life** (t½ = 0.693 × Vd/CL), it does NOT directly determine the elimination rate. - A large Vd means more drug in tissues, which affects how long elimination takes, but the actual rate of elimination is still determined by clearance. - Vd is a distribution parameter, not an elimination parameter. *All of the options* - This is incorrect because only **clearance** directly determines the rate of drug elimination. - While lipid solubility and volume of distribution can indirectly influence how long a drug remains in the body, they do not determine the elimination rate itself—clearance does.
Question 6: A hospital implements blockchain technology for maintaining electronic health records. Compared to traditional centralized database systems, what is the primary advantage that justifies this innovation from a healthcare quality perspective?
- A. Faster data retrieval for clinical decision-making
- B. Enhanced data integrity through immutable distributed ledger (Correct Answer)
- C. Reduced storage costs due to distributed architecture
- D. Simplified user interface for healthcare providers
Explanation: ***Enhanced data integrity through immutable distributed ledger*** - The primary feature of **blockchain** is its **immutability**, meaning once a record is added to the ledger, it cannot be altered without consensus from the network. - This ensures **data integrity** and creates a permanent, transparent **audit trail**, which is critical for reducing medical errors and preventing unauthorized tampering with health records. *Faster data retrieval for clinical decision-making* - Blockchain architecture often involves **consensus protocols** and distributed verification, which can actually make data retrieval or processing **slower** than traditional centralized databases. - The innovation's value lies in **security and trust**, not necessarily in the raw speed of clinical inquiry compared to high-speed SQL databases. *Reduced storage costs due to distributed architecture* - In a blockchain, the ledger is **replicated** across multiple nodes, which typically leads to **higher storage requirements** and costs rather than lower ones. - Each participating node must maintain a copy of the transactions, making the architecture inherently **more expensive** in terms of data redundancy. *Simplified user interface for healthcare providers* - Blockchain is a **back-end infrastructure** technology and does not inherently influence or improve the **user interface (UI)** or front-end experience. - The complexity of managing **cryptographic keys** can sometimes make the system more difficult for non-technical users to navigate compared to traditional systems.
Question 7: A biotech company proposes using induced pluripotent stem cells (iPSCs) derived from patient fibroblasts to generate personalized cardiomyocytes for myocardial infarction treatment. What is the most significant ethical and technical challenge that must be addressed before clinical application?
- A. Lack of vascularization in transplanted tissue
- B. Risk of teratoma formation and incomplete differentiation (Correct Answer)
- C. Rejection due to HLA mismatch
- D. High cost of production limiting accessibility
Explanation: ***Risk of teratoma formation and incomplete differentiation*** - Residual **undifferentiated pluripotent cells** pose a significant safety risk because they have the potential to grow into **tumors** (teratomas) after transplantation into the patient [1]. - Ensuring **purity** and complete differentiation into functional cardiomyocytes is the primary technical hurdle to avoid **oncogenic transformation** in clinical settings [1]. *Lack of vascularization in transplanted tissue* - While **diffusion limits** the survival of thick tissue grafts, this is an **engineering challenge** rather than a fundamental ethical or safety barrier like tumorigenicity. - Innovative approaches like **3D bioprinting** are being developed to address the blood supply issue for larger cardiac patches. *Rejection due to HLA mismatch* - A major advantage of using **patient-derived fibroblasts** to create **iPSCs** is that the resulting cells are **autologous**, meaning they are genetically identical to the recipient [1]. - Because the tissue is "self," the risk of **immunological rejection** and the need for immunosuppression are effectively eliminated. *High cost of production limiting accessibility* - Although the high cost and **resource-intensive** nature of personalized medicine present a public health challenge, it is classified as a **socioeconomic barrier**. - **Economic factors** are secondary to the immediate **clinical safety profile** required for regulatory approval and patient safety.
Question 8: An AI algorithm trained on chest X-rays from a single tertiary care center shows 95% accuracy in detecting tuberculosis. When deployed in a rural primary health center, accuracy drops to 68%. Which factor most likely explains this discrepancy?
- A. Hardware limitations at rural center
- B. Inadequate training of healthcare workers
- C. Dataset shift and lack of external validation (Correct Answer)
- D. Lower prevalence of tuberculosis in rural areas
Explanation: ***Dataset shift and lack of external validation*** - This phenomenon occurs when an AI model is trained on a specific population (tertiary center) but fails to generalize to a different population with distinct characteristics, known as **dataset shift**. - The absence of **external validation** means the algorithm was not tested on diverse datasets before deployment, leading to poor **generalizability** in different clinical environments. *Hardware limitations at rural center* - While varying **image resolution** or file formats can affect AI performance, they generally do not cause a massive drop in accuracy if the model is robustly designed. - Hardware differences are a technical barrier rather than a fundamental flaw in the **algorithmic logic** or statistical generalizability. *Inadequate training of healthcare workers* - AI accuracy is a measure of the algorithm's **predictive performance** on given images, independent of the clinical skills of the human operators. - Training workers on how to use the interface does not change the **mathematical output** or sensitivity/specificity of the model itself. *Lower prevalence of tuberculosis in rural areas* - While **prevalence** significantly affects **Positive Predictive Value (PPV)**, accuracy as a metric is generally driven by the model's inherent sensitivity and specificity. - Even if prevalence shifted, the drop in overall accuracy suggests the model is failing to correctly identify **true negatives or true positives** because the rural data distribution differs from the training set.
Question 9: A pharmaceutical company develops a new checkpoint inhibitor targeting LAG-3 (Lymphocyte Activation Gene-3) for melanoma. Compared to PD-1 inhibitors, what advantage would combination therapy with both agents theoretically provide?
- A. Dual blockade of different inhibitory pathways enhancing T-cell activation (Correct Answer)
- B. Complete elimination of immune-related adverse events
- C. Activation of humoral immunity instead of cellular immunity
- D. Reduced cost of treatment due to synergistic dosing
Explanation: Dual blockade of different inhibitory pathways enhancing T-cell activation - **LAG-3** and **PD-1** are distinct immune checkpoints that inhibit T-cell function via non-redundant pathways, and blocking both leads to a synergistic **re-activation of exhausted T-cells**. - This combination therapy allows the immune system to overcome **tumor-mediated immunosuppression** more effectively by targeting multiple receptors that limit the anti-tumor response [1]. *Complete elimination of immune-related adverse events* - **Immune-related adverse events (irAEs)** actually tend to increase in frequency and severity when multiple **checkpoints** are blocked simultaneously. - Dual inhibition enhances **systemic immune activation**, which raises the risk of inflammation in healthy organs like the colon, lungs, or endocrine glands. *Activation of humoral immunity instead of cellular immunity* - Both PD-1 and LAG-3 inhibitors primarily aim to enhance **T-cell (cellular) immunity**, specifically targeting **cytotoxic CD8+ T-cells** to kill tumor cells. - These agents do not shift the response toward **humoral (B-cell/antibody)** immunity as their primary mechanism of action in melanoma treatment. *Reduced cost of treatment due to synergistic dosing* - Combination therapies significantly **increase the cost** of treatment because two distinct and expensive **monoclonal antibodies** are being utilized. - There is no evidence that synergy allows for a significant reduction in dosage that would result in a lower financial burden for the patient.
Question 10: A 62-year-old diabetic patient is enrolled in a telemedicine program with remote monitoring. His continuous glucose monitor shows nocturnal hypoglycemia at 3 AM for three consecutive nights, but morning fasting glucose is elevated at 180 mg/dL. What is the most appropriate next step?
- A. Switch to morning insulin administration only
- B. Reduce evening insulin dose and provide bedtime snack (Correct Answer)
- C. Increase evening insulin dose to control morning hyperglycemia
- D. Add metformin to evening regimen
Explanation: Reduce evening insulin dose and provide bedtime snack - This presentation describes the Somogyi phenomenon, where nocturnal hypoglycemia triggers a surge in counter-regulatory hormones (like glucagon and cortisol), leading to rebound fasting hyperglycemia. - Remote Continuous Glucose Monitoring (CGM) is essential for identifying this pattern, as the primary intervention is to reduce evening insulin or provide a snack to prevent the 3 AM drop [1]. Switch to morning insulin administration only - Removing evening insulin entirely can lead to poor glycemic control throughout the night and uncontrolled basal glucose production. - Managing Type 2 diabetes usually requires a balanced basal-bolus or long-acting regimen that cannot be achieved with morning-only dosing. Increase evening insulin dose to control morning hyperglycemia - Increasing the evening dose would worsen the nocturnal hypoglycemia, potentially leading to dangerous seizures or coma during sleep [1]. - This is a common error when clinicians rely only on fasting glucose levels without checking midnight or 3 AM glucose values [1]. Add metformin to evening regimen - While Metformin suppresses hepatic gluconeogenesis, it does not address the underlying hypoglycemic trigger caused by insulin excess in this scenario. - Adding more glucose-lowering medication without adjusting the insulin would likely exacerbate the Somogyi effect rather than stabilize the patient.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free